NCT07265505Not yet recruiting
Study of Endometrial Immune and Microbiological Modifications in Cases of Recurrent Implantation Failure and/or Recurrent Pregnancy Loss
Study of Immune and Microbiological Modifications of the Endometrium in Cases of Recurrent Implantation Failure and/or Recurrent Pregnancy Loss
Source: ClinicalTrials.gov · Last updated 5 Feb 2026
Brief summary (registry, in English)
The IMERR study aims to improve understanding of certain causes of infertility related to recurrent implantation failure (RIF) and/or recurrent pregnancy loss (RPL), conditions that affect many women undergoing assisted reproductive technology (ART). Despite medical advances, some patients repeatedly fail to achieve pregnancy, or experience repeated miscarriages. These situations may be linked to subtle immune or microbial disturbances in the uterus. This study seeks to identify immune and microbiological profiles in the endometrium during the implantation window-a crucial period when the embryo attaches to the uterine wall. We will compare women who have experienced RIF and/or RPL with women who have had no such history. Blood and uterine samples will be analyzed to investigate whether certain immune or microbial features are associated with these reproductive failures. The ultimate goal is to uncover predictive factors that may explain why some women experience implantation failure or pregnancy loss, and to lay the foundation for future personalized treatments to improve reproductive outcomes.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- First submitted
- 26 May 2025
- Start date
- Apr 2026
- Primary completion date
- Apr 2029
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
- Diseases
- Endometriosis
- NCT number
- NCT07265505
What you commit to
- Study type: Interventional
- Planned participants: 100
- From Apr 2026 to the primary completion date, Apr 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Antibiotic use within one month prior to endometrial biopsy Positive serology for hepatitis B, hepatitis C or HIV
Other illness
- Known autoimmune disease, thrombophilia, or antiphospholipid antibody syndrome
Other
- Pregnant at inclusion
- Refusal to provide written informed consent
- Uterine anatomical abnormalities (e.g., polyps, cavity-distorting fibroids, untreated hydrosalpinx)
- Known chromosomal abnormality in either partner
- Persons under legal protection (e.g., guardianship, curatorship)
Who the study is looking for
- Female aged ≥18 and \<36 years
- Undergoing assisted reproductive technology (ART) in a fertility center
- Covered by the French national health insurance system
- Belonging to one of two groups:
- Study group: history of recurrent implantation failure (RIF) and/or recurrent pregnancy loss (RPL)
- Control group: no history of RIF or RPL
Age in the registry: 18 years to 35 years · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Service de Gynécologie Obstétrique II et Médecine de la Reproduction - Cochin Hospital Coordinator of this site? Confirm its status | Paris | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.